Corporate Profile
Scholar Rock is a
biopharmaceutical
company that discovers,
develops, and delivers
life-changing therapies
for people with serious
diseases that have high
unmet need. As a global
leader in the biology of
the transforming growth
factor beta (TGFβ)
superfamily of cell
proteins and named for
the visual resemblance
of a scholar rock to
protein structures, the
clinical-stage company
is focused on advancing
innovative treatments
where protein growth
factors are fundamental.
Over the past decade,
the company has created
a pipeline with the
potential to advance the
standard of care for
neuromuscular disease
and other conditions
where growth
factor-targeted drugs
can play a
transformational
role.
Scholar Rock is the only
company to show clinical
success for a
muscle-targeted
treatment in spinal
muscular atrophy (SMA).
This commitment to
unlocking fundamentally
different therapeutic
approaches is powered by
broad application of a
proprietary platform,
which has developed
novel monoclonal
antibodies to modulate
protein growth factors
with extraordinary
selectivity. By
harnessing cutting-edge
science in disease
spaces that are
historically
under-addressed through
traditional therapies,
Scholar Rock works every
day to create new
possibilities for
patients. Learn more
about the company’s
approach at
https://scholarrock.vercel.app
and follow
@ScholarRock
and on
LinkedIn.